PriceTargets.com logo

Definitive Healthcare - DH Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $17.00
  • Forecasted Upside: 65.37%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$10.28 As of 03/24/2023 01:00 AM ET
▼ -0.33 (-3.11%)

This chart shows the closing price for DH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Definitive Healthcare Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DH

Analyst Price Target is $17.00
▲ +65.37% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Definitive Healthcare in the last 3 months. The average price target is $17.00, with a high forecast of $26.00 and a low forecast of $13.00. The average price target represents a 65.37% upside from the last price of $10.28.

This chart shows the closing price for DH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 investment analysts is to hold stock in Definitive Healthcare. This rating has held steady since November 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
2/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/28/2023Morgan StanleyLower TargetOverweight$18.00 ➝ $17.00Low
2/24/2023Needham & Company LLCReiterated RatingBuy$15.00Low
2/24/2023Credit Suisse GroupLower TargetNeutral$19.00 ➝ $15.00N/A
1/6/2023Morgan StanleyLower TargetOverweight$21.00 ➝ $18.00Low
12/14/2022Robert W. BairdBoost Target$15.00Low
12/9/2022Bank of AmericaInitiated CoverageNeutral$13.00Low
11/7/2022The Goldman Sachs GroupLower TargetNeutral$31.00 ➝ $17.00Low
11/4/2022Morgan StanleyLower TargetOverweight$23.00 ➝ $21.00Low
11/4/2022Needham & Company LLCLower TargetBuy$32.00 ➝ $15.00Low
11/4/2022Credit Suisse GroupLower TargetNeutral$24.00 ➝ $19.00Low
10/24/2022Morgan StanleyLower TargetOverweight$34.00 ➝ $23.00Low
10/11/2022BarclaysLower Target$23.00 ➝ $18.00Low
8/8/2022BarclaysLower TargetEqual Weight$24.00 ➝ $23.00Low
8/8/2022Morgan StanleyLower TargetOverweight$37.00 ➝ $34.00Low
7/6/2022Needham & Company LLCInitiated CoverageBuy$30.00N/A
4/5/2022Deutsche Bank AktiengesellschaftBoost TargetHold$21.00 ➝ $26.00N/A
2/24/2022Canaccord Genuity GroupUpgradeHold ➝ BuyHigh
2/24/2022Canaccord Genuity GroupUpgradeHold ➝ Buy$46.00 ➝ $28.00High
2/24/2022BarclaysLower Target$26.00 ➝ $23.00High
2/24/2022Credit Suisse GroupLower TargetNeutral$30.00 ➝ $24.00High
1/25/2022Deutsche Bank AktiengesellschaftLower TargetHold$45.00 ➝ $21.00High
1/19/2022BarclaysLower TargetEqual Weight$47.00 ➝ $26.00High
12/16/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$46.00 ➝ $40.00Low
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$36.00Low
11/16/2021Robert W. BairdInitiated CoverageOutperform$50.00High
11/10/2021Deutsche Bank AktiengesellschaftLower TargetHold$47.00 ➝ $45.00Low
10/11/2021JPMorgan Chase & Co.Initiated CoverageNeutral$47.00High
10/11/2021Stifel NicolausInitiated CoverageBuy$53.00High
10/11/2021Raymond JamesInitiated CoverageMarket PerformHigh
10/11/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold$47.00High
10/11/2021Credit Suisse GroupInitiated CoverageNeutral$50.00High
10/11/2021Morgan StanleyInitiated CoverageEqual Weight$46.00High
10/11/2021BarclaysInitiated CoverageEqual Weight$47.00High
10/11/2021The Goldman Sachs GroupInitiated CoverageNeutral$34.00High
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.72 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/27/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 4 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/26/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 7 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 7 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Definitive Healthcare logo
Definitive Healthcare Corp., together with its subsidiaries, provides healthcare commercial intelligence in the United States. Its solutions provide information on healthcare providers and their activities to help its customers in the area ranging from product development to go-to-market planning, and sales and marketing execution. The company's platform offers 16 intelligence modules that cover functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate companies, financial institutions, and other organizations in the healthcare ecosystem. Definitive Healthcare Corp. was founded in 2011 and is headquartered in Framingham, Massachusetts.
Read More

Today's Range

Now: $10.28
Low: $10.12
High: $10.68

50 Day Range

MA: $12.02
Low: $10.28
High: $14.01

52 Week Range

Now: $10.28
Low: $9.53
High: $30.11

Volume

719,499 shs

Average Volume

1,074,604 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Definitive Healthcare?

The following Wall Street analysts have issued research reports on Definitive Healthcare in the last year: Bank of America Co., Barclays PLC, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Morgan Stanley, Needham & Company LLC, Robert W. Baird, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for DH.

What is the current price target for Definitive Healthcare?

8 Wall Street analysts have set twelve-month price targets for Definitive Healthcare in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 65.4%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting DH will reach $26.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $13.00 for Definitive Healthcare in the next year.
View the latest price targets for DH.

What is the current consensus analyst rating for Definitive Healthcare?

Definitive Healthcare currently has 5 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DH, but not buy more shares or sell existing shares.
View the latest ratings for DH.

What other companies compete with Definitive Healthcare?

Other companies that are similar to Definitive Healthcare include Certara, USANA Health Sciences, ModivCare, Arcus Biosciences and Cytek Biosciences. Learn More about companies similar to Definitive Healthcare.

How do I contact Definitive Healthcare's investor relations team?

Definitive Healthcare's physical mailing address is 550 COCHITUATE ROAD, FRAMINGHAM MA, 01701. The company's listed phone number is 508-720-4224 and its investor relations email address is [email protected] The official website for Definitive Healthcare is www.definitivehc.com. Learn More about contacing Definitive Healthcare investor relations.